# A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.

> **NCT02417285** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 75 (actual)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** CC-122

## Key facts

- **NCT ID:** NCT02417285
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-22
- **Primary completion:** 2019-05-27
- **Final completion:** 2023-09-28
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02417285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02417285, "A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02417285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*